Letter to the Editor
Split Viewer
Blood Res 2016; 51(1):
Published online March 31, 2016
https://doi.org/10.5045/br.2016.51.1.66
© The Korean Society of Hematology
Steroid-refractory immune thrombocytopenia in the era of the new thrombomimetic drugs: is there still a role for rituximab?
Hematology Unit, Sant'Eugenio Hospital, Rome, Italy.
Correspondence to : Pasquale Niscola. Hematology Unit, Sant'Eugenio Hospital, Piazzale dell'Umanesimo, 10, Roma 00144, Italy. pniscola@gmail.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
REFERENCES
- Provan, D, Stasi, R, Newland, AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, 2010;115;168-186.
- Ozkan, MC, Sahin, F, Saydam, G. Immune thrombocytopenic purpura: new biological therapy of an old disease. Curr Med Chem, 2015;22;1956-1962.
- Godeau, B, Stasi, R. Is B-cell depletion still a good strategy for treating immune thrombocytopenia?. Presse Med, 2014;43;e79-e85.
- Kim, YK, Lee, SS, Jeong, SH, et al. Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia. Blood Res, 2015;50;19-25.
- Scaramucci, L, Giovannini, M, Niscola, P, Tendas, A, Perrotti, A, De Fabritiis, P. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura. Blood Transfus, 2014;12;605-607.
PDF
Standard view
Export citation
Share Article
Letter to the Editor
Blood Res 2016; 51(1): 66
Published online March 31, 2016 https://doi.org/10.5045/br.2016.51.1.66
Copyright © The Korean Society of Hematology.
Steroid-refractory immune thrombocytopenia in the era of the new thrombomimetic drugs: is there still a role for rituximab?
Massimiliano Palombi, Laura Scaramucci, Marco Giovannini, Malgorzata Monika Trawinska, Pasquale Niscola*, and Paolo de Fabritiis
Hematology Unit, Sant'Eugenio Hospital, Rome, Italy.
Correspondence to: Pasquale Niscola. Hematology Unit, Sant'Eugenio Hospital, Piazzale dell'Umanesimo, 10, Roma 00144, Italy. pniscola@gmail.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
- Provan, D, Stasi, R, Newland, AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, 2010;115;168-186.
- Ozkan, MC, Sahin, F, Saydam, G. Immune thrombocytopenic purpura: new biological therapy of an old disease. Curr Med Chem, 2015;22;1956-1962.
- Godeau, B, Stasi, R. Is B-cell depletion still a good strategy for treating immune thrombocytopenia?. Presse Med, 2014;43;e79-e85.
- Kim, YK, Lee, SS, Jeong, SH, et al. Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia. Blood Res, 2015;50;19-25.
- Scaramucci, L, Giovannini, M, Niscola, P, Tendas, A, Perrotti, A, De Fabritiis, P. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura. Blood Transfus, 2014;12;605-607.
Previous Article
